Assessment of the markers of platelet and coagulation activation following transcatheter closure of atrial septal defects

Background: Aspirin has been routinely prescribed following transcatheter closure of secundum atrial septal defects (ASDs) but its rationale has not been clinically or biologically evaluated; and despite aspirin, thrombotic complications occur following transcatheter ASD closure. We therefore evalua...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cardiology 2005-01, Vol.98 (1), p.107-112
Main Authors: Rodés-Cabau, Josep, Palacios, Andrés, Palacio, Carles, Girona, Josep, Galve, Enrique, Evangelista, Arturo, Casaldáliga, Jaume, Albert, Dipma, Picó, Marta, Soler-Soler, Jordi
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Amplatzer septal occluder
Atrial septal defects
Biological and medical sciences
Biomarkers - blood
Blood Coagulation
Cardiac Catheterization
Cardiology. Vascular system
Coagulation
Congenital heart diseases. Malformations of the aorta, pulmonary vessels and vena cava
Embolization, Therapeutic - instrumentation
Female
Flow Cytometry
Follow-Up Studies
Heart
Heart Septal Defects, Atrial - blood
Heart Septal Defects, Atrial - surgery
Humans
Male
Medical sciences
Middle Aged
Platelet Activation
Platelets
Prospective Studies
Research Design
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Aspirin has been routinely prescribed following transcatheter closure of secundum atrial septal defects (ASDs) but its rationale has not been clinically or biologically evaluated; and despite aspirin, thrombotic complications occur following transcatheter ASD closure. We therefore evaluated the presence, degree and timing of the activation of the coagulation and platelet systems following transcatheter closure of ASDs. Methods and results: Fourteen consecutive patients (9 females, mean age 41±22 years) who underwent successful transcatheter closure of an ASD defect with the Amplatzer septal occluder were prospectively studied. Measurements of the prothrombin fragment 1+2 (F1+2) levels and the percentage of activated platelets (determined by P-selectin expression detected by flow cytometry) were taken at baseline just before the procedure, and at 1, 7, 30 and 90 days following device implantation. F1+2 levels increased from 0.85±0.29 nmol/l at baseline to a maximal value of 1.20±0.52 nmol/l at 7 days, gradually returning to the baseline levels at 90 days (0.79±0.54 nmol/l) ( p
ISSN:0167-5273
1874-1754
DOI:10.1016/j.ijcard.2004.03.022